Weight loss and antidiabetic drugs are part of the NAFLD therapy and can eventually lead to a resolution of NASH [40] and are therefore a confounding factor regarding ALT levels. This evidence concerns the gene GPT and metabolic dysfunction-associated steatotic liver disease.